去勢抵抗型前列腺癌的治療進展
發(fā)布時間：2018-09-11 06:03
【摘要】：前列腺癌是在老年男性中發(fā)病率較高惡性腫瘤。在歐洲個別國家，前列腺癌早已超過肺癌的發(fā)病率，位居為首位。而在我國，由于現(xiàn)在人們生活習性方式、飲食習性的不斷變化和老年男性構成比越來越大，前列腺癌的發(fā)病率也出現(xiàn)朝不斷上升的勢頭，并且發(fā)病年齡逐漸呈現(xiàn)年輕化發(fā)展。目前前列腺癌的主要治療方式為前列腺根治術、內分泌治療、化療、放療。但是多數(shù)患者診斷時已經(jīng)多處于晚期，失去了手術根治機會，，并且絕大多數(shù)患者在內分泌治療過程當中，初始階段治療效果可，但是幾乎所有最初對內分泌治療敏感的患者在經(jīng)過一段時間后都可能發(fā)展成為CRPC。如果發(fā)展成為CRPC，勢必會給臨床醫(yī)生在治療放療帶來棘手的問題，而且如治療效果不佳，嚴重時患者有生命危險可能。臨床上CRPC是前列腺癌死亡的重要原因，近年來美國FDA批準了多種新藥用于CRPC的治療，如卡巴他賽、新型雄激素合成抑制劑（阿比特龍，TAK-700）、雄激素受體拮抗劑（MDV3100）、狄諾塞麥（Denosumab）以及新的免疫療法（Sipuleucel-T）等，還有一些正在進行臨床試驗的新藥，如Ixabepilone、普利姆瑪（lpilimumab）、阿曲生坦(Atrasentan， Xinlay)等等。
[Abstract]:Prostate cancer is associated with a higher incidence of malignant tumors in older men. In individual European countries, prostate cancer has long exceeded the incidence of lung cancer, ranking first. But in our country, because of the living habits of people, the changing of diet habits and the increasing proportion of the old men, the incidence of prostate cancer is also rising, and the age of the disease is developing younger. At present, prostate cancer is mainly treated by radical prostatectomy, endocrine therapy, chemotherapy, radiotherapy. However, most of the patients have been in the late stage of diagnosis, they have lost the opportunity of radical surgery, and most of the patients have been treated effectively in the initial stage of endocrine therapy. But almost all patients who were initially sensitive to endocrine therapy could develop CRPC. over time. If it develops into CRPC, it will inevitably bring the clinician a difficult problem in the treatment of radiotherapy, and if the treatment effect is not good, the patient may be at risk of life in severe cases. Clinically, CRPC is an important cause of death from prostate cancer. In recent years, FDA in the United States has approved a variety of new drugs for the treatment of CRPC, such as carbatin. New androgen synthesis inhibitors (Abidrol TAK-700) androgen receptor antagonists (MDV3100) Dinosemer (Denosumab) and new immunotherapy (Sipuleucel-T) as well as some new drugs in clinical trials such as Ixabepilone, Plimma (lpilimumab), Atrixantan (Atrasentan, Xinlay) and so on.
【學位授予單位】：重慶醫(yī)科大學
【學位級別】：碩士
【學位授予年份】：2014
【分類號】：R737.25
[Abstract]:Prostate cancer is associated with a higher incidence of malignant tumors in older men. In individual European countries, prostate cancer has long exceeded the incidence of lung cancer, ranking first. But in our country, because of the living habits of people, the changing of diet habits and the increasing proportion of the old men, the incidence of prostate cancer is also rising, and the age of the disease is developing younger. At present, prostate cancer is mainly treated by radical prostatectomy, endocrine therapy, chemotherapy, radiotherapy. However, most of the patients have been in the late stage of diagnosis, they have lost the opportunity of radical surgery, and most of the patients have been treated effectively in the initial stage of endocrine therapy. But almost all patients who were initially sensitive to endocrine therapy could develop CRPC. over time. If it develops into CRPC, it will inevitably bring the clinician a difficult problem in the treatment of radiotherapy, and if the treatment effect is not good, the patient may be at risk of life in severe cases. Clinically, CRPC is an important cause of death from prostate cancer. In recent years, FDA in the United States has approved a variety of new drugs for the treatment of CRPC, such as carbatin. New androgen synthesis inhibitors (Abidrol TAK-700) androgen receptor antagonists (MDV3100) Dinosemer (Denosumab) and new immunotherapy (Sipuleucel-T) as well as some new drugs in clinical trials such as Ixabepilone, Plimma (lpilimumab), Atrixantan (Atrasentan, Xinlay) and so on.
【學位授予單位】：重慶醫(yī)科大學
【學位級別】：碩士
【學位授予年份】：2014
【分類號】：R737.25
【參考文獻】
相關期刊論文 前3條
1 于永剛;;前列腺癌的放射治療[J];臨床外科雜志;2006年02期
2 張曉智;黃珊;;要重視放射治療在前列腺癌治療中的作用[J];現(xiàn)代泌尿外科雜志;2011年03期
3 喻彬;須霆;鄒青;楊爾p
本文編號：2235795
本文鏈接：http://sikaile.net/yixuelunwen/mjlw/2235795.html
最近更新
教材專著
